GSK2033 is primarily utilized in research settings as a selective inhibitor of the LXRβ (Liver X Receptor beta) nuclear receptor. It is widely used in studies aimed at understanding the role of LXRβ in metabolic processes, including cholesterol homeostasis, lipid metabolism, and inflammation. Researchers employ GSK2033 to investigate its potential therapeutic effects in diseases such as atherosclerosis, diabetes, and neurodegenerative disorders. Its specificity for LXRβ makes it a valuable tool for dissecting the distinct functions of LXR isoforms (LXRα and LXRβ) in cellular and animal models. Additionally, GSK2033 is used to explore its impact on gene regulation and signaling pathways associated with LXRβ activation, contributing to the development of targeted therapies for metabolic and inflammatory conditions.